Detailed Intravascular Ultrasound Analysis of Zotarolimus-Eluting Phosphorylcholine-Coated Cobalt-Chromium Alloy Stent in de Novo Coronary Lesions (Results from the ENDEAVOR II Trial)††Conflicts of interest: Dr. Fitzgerald has worked as a consultant for Medtronic Vascular. Dr. Kuntz is currently an employee of Medtronic Vascular.

American Journal of Cardiology

Volumn 100, Issue 5, 2007, Pages 818-823

  Sakurai, Ryota ^a   Hongo, Yoichiro ^a   Yamasaki, Masao ^a   Honda, Yasuhiro ^a   Bonneau, Heidi N ^b   Yock, Paul G ^a   Cutlip, Donald ^c   Popma, Jeffrey J ^c   Zimetbaum, Peter ^c   Fajadet, Jean ^d   Kuntz, Richard E ^c   Wijns, William ^e   Fitzgerald, Peter J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b Highlands Consulting Inc   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d CLINIQUE PASTEUR   (France)

^e CARDIOVASCULAR CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 578; CHROMIUM DERIVATIVE; COBALT; PHOSPHORYLCHOLINE; RAPAMYCIN DERIVATIVE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ADULT; AGED; APPARATUS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INTIMA; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

CHROMIUM ALLOYS; COATED MATERIALS, BIOCOMPATIBLE; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DOUBLE-BLIND METHOD; ENDOSONOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; PROSPECTIVE STUDIES; SIROLIMUS; STENTS; TUNICA INTIMA;

EID: 34547936323     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.04.016     Document Type: Article

References (7)

1. Fajadet J., Wijns W., Laarman G.J., Kuck K.H., Ormiston J., Munzel T., Popma J.J., Fitzgerald P.J., Bonan R., and Kuntz R.E. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114 (2006) 798-806
2. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Weissman N.J., Koglin J., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., et al. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1201-1205
4. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
5. Hirohata A., Morino Y., Ako J., Sakurai R., Buchbinder M., Caputo R.P., Karas S.P., Mishkel G.J., Mooney M.R., O'Shaughnessy C.D., et al. Comparison of the efficacy of direct coronary stenting with sirolimus-eluting stents versus stenting with predilation by intravascular ultrasound imaging (from the DIRECT trial). Am J Cardiol 98 (2006) 1464-1467
6. Tanabe K., Serruys P.W., Degertekin M., Guagliumi G., Grube E., Chan C., Munzel T., Belardi J., Ruzyllo W., Bilodeau L., et al. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation 109 (2004) 196-200
7. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421